#U.S. Next Generation Diabetes Therapy and Drug Delivery Market size | Explore Tumblr Posts and Blogs

kdmarketresearch · 5 years

Text

U.S. Next Generation Diabetes Therapy and Drug Delivery Market – Top players Abbott Laboratories,Echo Therapeutics, Inc.,F. Hoffmann-La Roche Ltd, GlySens Incorporated, Medtronic Plc, Sanofi, Novo Nordisk, MannKind Corporation, Dexcom, Inc, Senseonics Holding, Inc.

KD Market research has presented a detailed report on “U.S. Next Generation Diabetes Therapy and Drug Delivery Market ” which includes the major application, advantages, and key market trends that are fostering the growth of the market during the forecasted span of 6 years. The research takes a step forward and analyzes the key competitors and global regions that are holding the market share of U.S. Next Generation Diabetes Therapy and Drug Delivery Market in terms of revenue.

Request for sample@ https://www.kdmarketresearch.com/sample/3441

The U.S. next generation diabetes therapy and drug delivery market was valued at $446 million in 2015, and is estimated to reach $6,510 million by 2023, registering a CAGR of 33.0% from 2017 to 2023. Next generation diabetes therapy and drug delivery devices are used to accurately check the blood glucose levels and deliver insulin into the body. Next generation diabetes drug delivery systems such as oral and inhalable insulin help to introduce insulin into the patient?s body without causing pain and also reduces the risk of skin irritation due to frequent use of needles.

The U.S. next generation diabetes therapy and drug delivery market is segmented based on product type, demographic, end user, and region. The product type segment includes inhalable insulin, oral insulin, insulin patch, continuous glucose monitoring systems (CGMS), and artificial pancreas. Based on demographic, the market is bifurcated into adult population (>14years) and child population (=14years). Based on indication, the market is divided into diabetes I and II. Based on end user, the market is categorized into diagnostics/clinic, ICU, and home healthcare.

Rise in the number of diabetic cases and the benefits of using these advanced devices over conventional products boost the market growth. The well-established healthcare infrastructure and high R&D activities for the advancement in diabetes therapeutic technology are expected to provide opportunities for market growth. However, less variability in products and cost restraints among low and middle-income population are expected to hinder the market growth. Development of affordable products with fewer side effects and presence of undiagnosed diabetic patients in the U.S. are projected to help to open new doors for the growth of the next generation diabetes therapy and drug delivery market.

KEY MARKET BENEFITS This report offers a detailed quantitative analysis of the current market trends from 2014 to 2023 to identify the prevailing opportunities. The market estimations provided are based on comprehensive analysis of the key developments in the industry. The U.S. next generation diabetes therapy and drug delivery market is comprehensively analyzed with respect to product type, demographics, indications, and end user. The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Product Type Inhalable Insulin Oral Insulin Insulin Patch CGM System Artificial Pancreas

By Demographic Adult Population (>14 years) Child Population (=14 years)

By End User Diagnostics/Clinic ICU Home Healthcare

KEY PLAYERS PROFILED Abbott Laboratories Echo Therapeutics, Inc. F. Hoffmann-La Roche Ltd. GlySens Incorporated Medtronic Plc Sanofi Novo Nordisk MannKind Corporation Dexcom, Inc. Senseonics Holding, Inc.

The other players of the catheters market include (companies not profiled in the report): Synertech Zosano Pharma Corp. Relmada Therapeutics, Inc. Eli Lilly and Company Enteris BioPharma Transdermal Specialties Inc

browse full report with toc@ https://www.kdmarketresearch.com/report/3441/us-next-generation-diabetes-therapy-and-drug-delivery-market-amr

Table of content

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION 1.2. KEY BENEFITS 1.3. KEY MARKET SEGMENTS 1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. KEY BENEFITS

3.1.1. Top investment pockets 3.1.2. Top winning strategies

3.2. PATENT ANALYSIS

3.2.1. Patent analysis by year 3.2.2. Patent analysis by product

3.3. GOVERNMENT REGULATIONS

3.3.1. U.S. FDA

3.4. REIMBURSEMENT POLICIES 3.5. INNOVATIONS IN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET

3.5.1. Smart contact lenses for glucose monitoring 3.5.2. iLet bihormonal bionic pancreas 3.5.3. Glucose nanosensors 3.5.4. Beta cell replacement therapy 3.5.5. Glucose-responsive insulin-producing cells

3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Rise in incidence of diabetes 3.6.1.2. Rise in healthcare expenditure & disposable income 3.6.1.3. Benefits of using next generation diabetes products over conventional products

3.6.2. Restraints

3.6.2.1. Cost restrains 3.6.2.2. Lack of awareness 3.6.2.3. Less variability in products

3.6.3. Opportunities

3.6.3.1. Developing products with fewer side effects at affordable costs 3.6.3.2. High undiagnosed diabetic patient population

CHAPTER 4 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. INHALABLE INSULIN

4.2.1. Key market trends 4.2.2. Key growth factors and opportunities 4.2.3. Market size and forecast

4.3. ORAL INSULIN

4.3.1. Key market trends 4.3.2. Key growth factors and opportunities 4.3.3. Market size and forecast

4.4. INSULIN PATCHES

4.4.1. Key market trends 4.4.2. Key growth factors and opportunities 4.4.3. Market size and forecast

4.5. CGMS

4.5.1. Key market trends 4.5.2. Key growth factors and opportunities 4.5.3. Market size and forecast

4.6. ARTIFICIAL PANCREAS

4.6.1. Key market trends 4.6.2. Key growth factors and opportunities 4.6.3. Market size and forecast

CHAPTER 5 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ADULT POPULATION (>14YEARS)

5.2.1. Market size and forecast

5.3. CHILD POPULATION (14YEARS)

5.3.1. Market size and forecast

CHAPTER 6 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. TYPE I DIABETES

6.2.1. Market size and forecast

6.3. TYPE II DIABETES

6.3.1. Market size and forecast

CHAPTER 7 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. DIAGNOSTICS/CLINICS

7.2.1. Market size and forecast

7.3. INTENSIVE CARE UNITS (ICU)

7.3.1. Market size and forecast

7.4. HOME HEALTHCARE

7.4.1. Market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. ABBOTT LABORATORIES

8.1.1. Company overview 8.1.2. Company snapshot 8.1.3. Operating business segments 8.1.4. Product portfolio 8.1.5. Business performance 8.1.6. Key strategic moves and developments

8.2. DEXCOM, INC.

8.2.1. Company overview 8.2.2. Company snapshot 8.2.3. Product portfolio 8.2.4. Business performance 8.2.5. Key strategic moves and developments

8.3. ECHO THERAPEUTICS, INC.

8.3.1. Company overview 8.3.2. Company snapshot 8.3.3. Operating business segments 8.3.4. Product portfolio

8.4. F. HOFFMANN-LA ROCHE LTD.

8.4.1. Company overview 8.4.2. Company snapshot 8.4.3. Operating business segments 8.4.4. Product portfolio 8.4.5. Business performance 8.4.6. Key strategic moves and developments

8.5. GLYSENS INCORPORATED

8.5.1. Company overview 8.5.2. Company snapshot 8.5.3. Product portfolio 8.5.4. Key strategic moves and developments

8.6. MANNKIND CORPORATION

8.6.1. Company overview 8.6.2. Company snapshot 8.6.3. Operating business segments 8.6.4. Product portfolio 8.6.5. Business performance

8.7. MEDTRONIC PLC.

8.7.1. Company overview 8.7.2. Company snapshot 8.7.3. Operating business segments 8.7.4. Product portfolio 8.7.5. Business performance 8.7.6. Key strategic moves and developments

8.8. NOVO NORDISK A/S

8.8.1. Company overview 8.8.2. Company snapshot 8.8.3. Operating business segments 8.8.4. Product portfolio 8.8.5. Business performance

8.9. SANOFI

8.9.1. Company overview 8.9.2. Company snapshot 8.9.3. Operating business segments 8.9.4. Product portfolio 8.9.5. Business performance 8.9.6. Key strategic moves and developments

8.10. SENSEONICS HOLDINGS, INC.

8.10.1. Company overview 8.10.2. Company snapshot 8.10.3. Operating business segments 8.10.4. Product portfolio 8.10.5. Business performance 8.10.6. Key strategic moves and developments

Check for discount @ https://www.kdmarketresearch.com/discount/3441

About Us:

KD Market Research is one of the best market research organization that provides B2B research on the growth opportunities of the industry which is the prime factor of the overall revenue of the organization. We identify the pain points which our client is facing around revenue methods and provide them with a comprehensive database which helps them to make intelligent decisions that could ensure growth to the organization.

Our Services include market intelligence, competitive intelligence, and customized research. These research reports help the organizations to make quick and powerful decisions that make out highest growth in revenue.

150 State Street, Albany,

New York, USA 12207

Email id [email protected]

#U.S. Next Generation Diabetes Therapy and Drug Delivery Market size #U.S. Next Generation Diabetes Therapy and Drug Delivery Market trends #U.S. Next Generation Diabetes Therapy and Drug Delivery Market opportunity #U.S. Next Generation Diabetes Therapy and Drug Delivery Market forecast

0 notes

market-research-future · 4 years

Text

Africa Medical Devices Market Opportunities, Dynamics, Global Industry Analysis

Africa Medical Devices Market Information, by Product type (Monitoring Devices, Diagnostic devices, Diagnostic Molecular Devices, Drug delivery devices, Surgical Devices, Bio implants and Stimulation Devices, Automation and Robotics and Others), by Therapeutic Application (General Surgery, Diagnostic Imaging, Respiratory, Orthopedics, Cardiovascular, Dental, Neurology, Ophthalmology, Ear-Nose-Throat (ENT), Nephrology and Urology, and Others) and by End User (Hospitals, Ambulatory and Home) - Forecast to 2023

Africa Medical Devices Market Regional Analysis

The Africa Medical Devices Market is growing rapidly in Africa region owing to upgrade of hospitals, introduction of health insurance policy, and rapidly growing middle-income group. Government is focussing more to improve the life of their citizen, thus they are more focusing on the establishment of best hospitals in the region. This region is more focusing towards new technology and advance treatment option; thus the local players are focusing more into mergers and acquisition and research and development programs for the development of Medical devices. These are the factors which are fuelling the growth of the market of medical devices with the significant rates in this region.

Company such as Koninklijke Philips Electronics NV, Siemens AG, Medtronic Public Limited, and GE Healthcare have already a huge presence in Africa region owing to the collaboration they made and strategy of expanding their sales network within the region. The markets of Africa region are very different and still shaping and growing. Although most of the products are imported within the region, but the government is focusing to develop this equipment in their premises to minimize the cost of medical devices.

Competitive Analysis

Companies are continuously engaged in merger and acquisition activities for the development of the best medicine to cure affected population. Although the government stick rule hindering the growth of the market. In May 2017, Baxter International Inc. and Mayo Clinic announced a collaboration for the research and development to advance a spectrum of therapeutic areas to minimize the unmet patient needs. These collaborations help market players to lead the Africa Medical Devices Market. Most of the players from this region involve in the collaboration with global players to get advanced technology, which help them to maximize the market share in this region. Although limited infrastructure, lack of physicians, and restricted funding and reimbursement policy are the restraints factor for the growth of the market.

Johnson & Johnson (U.S.), Mindray Medical International Limited (China), Koninklijke Philips Electronics NV (Netherlands), Siemens AG (Germany), Toshiba Medical Systems Corporation (Japan), GE Healthcare (U.K), Medtronic Public Limited (U.S.), Baxter International Inc. (U.S.), Cardinal Health, Inc. (U.S.), Saudi Pharmaceutical Industries & Medical Appliances Corporation (Africa), and Al Faisaliah Medical Systems (Africa) are some of the leading players at the cutting edge of the competition in the Africa Medical Devices Market

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1813

Overview

Any instrument, apparatus, implement, implant, reagent that is used for human beings, for diagnosis, detecting, restoring, correcting, prevention, monitoring, treatment of disease and injury are known as medical devices. Technological advancement plays an important role in the growth of any sector. Most of the market players play an important role to develop the market of medical devices in Africa. For instance, in 2015, Elekta and ministry of health working together in almost a dozen African nations to develop their radiation therapy infrastructures for curing lives.

It is expected that Africa’s macroeconomic climate over the next decade will expand the health care gap, as higher incomes will create new demand for the medical devices market. Additionally, government also introduces some laws for maintaining the quality of medical devices. According to a report published by the International Diabetes Federation, in 2017, more than 16 million people are suffering with diabetes in the AFR Region. Increasing number of incidences are the main factors which drag the attention of players towards this region.

Moreover, rising economic growth also drive the market in this region. According to the World Bank Group, in 2016, GDP of the Middle East & North Africa experienced the growth in GDP by 4.89%.

Browse Detailed Table of Content at: https://www.marketresearchfuture.com/reports/africa-medical-devices-market-2845

Brows More Healthcare Related Research Reports:

Infrared Spectroscopy Devices Market Size, Trends | Growth Analysis, 2023

Asia-Pacific Glaucoma Treatment Market Trends, Size Analysis | Applications, 2023

Diabetes Market Research Report Forecast To 2023 | MRFR

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]

0 notes

technicallyyoungkitten · 4 years

Text

Wearable Patch Market- Size, Share, Outlook, and Opportunity Analysis, 2020- 2027

Wearable patches are known as smart patches or electronic skin. These are thin, small, and flexible in nature, and are used for disease monitoring, drug delivery, and diagnosis. Wearable patches help to maintain health and wellbeing in elderly patients suffering from chronic conditions such as diabetes and others. Presently, the market of wearable technologies is growing, owing to increasing research and development activities for development of wearable patch carried out by key players operating in the market. Wearable patches can be worn or stuck to the skin, or patch’s such as scopolamine patches and transdermal patch are directly attached to the affected body part for disease monitoring. For instance, a nicotine path is a transdermal patch, which releases nicotine into the body, and is used in nicotine replacement therapy (NRT).

Request a sample copy of this report:- https://www.coherentmarketinsights.com/insight/request-sample/2891

The global wearable patch market size is expected to be valued at US$ 318.1 million in 2019, and is expected to exhibit a CAGR of 22.9% over the forecast period (2019-2027).

Increasing prevalence of chronic diseases such as diabetes and atrial fibrillation is resulting in high number of stroke incidents, which is expected to drive growth of the wearable patch market over the forecast period. For instance, according to the International Diabetes Federation report published in November 2019, around 463 million adults between the age group of 20 to 79 years were diagnosed with diabetes across the globe, and it is expected that the total diabetes population will reach around 700 million by 2045 globally.

Moreover, according to the American Heart Association, January 2019, stroke was a leading cause of death in the U.S. with around 2.7 million people in the country living with atrial fibrillation and around 800,000 people encounter stroke, annually, due to blockage in the blood vessel, which supplies blood to the brain. Therefore, increasing prevalence of atrial fibrillation is expected to boost growth of the wearable patch market.

Wearable patches are used for monitoring and diagnosis of chronic diseases. Increasing prevalence of diseases such as atrial fibrillation has led to increase in demand for wearable patches for early diagnosis. This rising demand has led by major players in the market to launch new and technologically advanced wearable patch. For instance, in July 2018, LifeSignals, a solution provider for health and wellbeing, received the U.S. Food and Drugs Administration (FDA) approval for wireless LP1100 Life Signal Patch, a next generation wearable healthcare monitoring device. LP1100 Life Signal Patch is a clinical-grade, two-lead ECG, and heart rate monitoring patch, which has three-day monitoring capacity.

Furthermore, in November 2018, L’Oreal and La Roche-Posay launched ‘My Skin Track UV’, a wearable skin and sun safety sensor to help women and men to track their personalized exposure to UV, pollution, pollen, and humidity.

However, high cost of sensor monitoring patch is expected to hinder growth market growth in emerging economies such as India, Brazil and China. The average price of ECG sensor patch is around US$ 300 to US$ 4,500. Market players, who can address the cost issue and can offer high quality products in emerging economies are expected to enhance their market share in the particular region.

Major players operating in the global wearable patch market include Medtronic Plc, Hill-Rom Holdings, Inc. (Welch Allyn), iRhythm Technologies, Inc., AliveCor, Inc., Vivalnk, Inc., Cardiac Insight Inc., VitalConnect, LifeSignals, Inc., L’oreal Group, Dexcom, Inc., GENTAG, Inc., Abbott Laboratories, and Koninklijke Philips N.V.

Get the main link:- https://www.coherentmarketinsights.com/market-insight/wearable-patch-market-2891

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Visit our news Website: http://www.coherentchronicle.com/

0 notes

adwaitcoherent · 4 years

Text

By 2027 Wearable Patch Market To Surpass US$ 1,660.5 Million - Coherent Market Insights

From 2019-2027 Wearable Patch Market To reach CAGR of 22.5%

Request for Sample PDF Copy:

https://www.coherentmarketinsights.com/insight/request-pdf/2891

Description:

The global wearable patch market size is expected to be valued at US$ 318.1 million in 2019, and is expected to exhibit a CAGR of 22.9% over the forecast period (2019-2027).

Figure 1. Global Wearable Patch Market Value (US$ Mn), by Region, 2019

Wearable Patch | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Increasing prevalence of chronic diseases is expected to propel the market growth over the forecast period

Figure 2. Global Wearable Patch Market Share (%), by Application, 2027

Wearable Patch | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Rising technological advancements in wearable patch is anticipated to drive the market growth over the forecast period

Key Players

About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We do offer wide range of services such as Industry analysis, Consulting services, Market Intelligence, Customized research services and much more. We have expertise in many fields such as healthcare, chemicals and materials, Automation, semiconductors, electronics, energy, food and beverage, packaging and many more. Visit our website to know more.

Buy Report Here:

https://www.coherentmarketinsights.com/insight/buy-now/2891

Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave. #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]

#Market Analysis #Market Research #Coherent Market Insights

0 notes

niranjan20 · 4 years

Link

U.S. next generation diabetes therapy and drug delivery market is growing at a CAGR of 33.0%, projected to reach $6,510 million by 2023.

#U.S. NextGeneration Diabetes Therapy and Drug Delivery Market

0 notes

ellinahussey · 4 years

Text

Human Microbiome Market Size & Share, Application Analysis, Regional Outlook, Growth Trends, Key Players and Competitive Strategies - Forecast to 2025

Human Microbiome Market is valued at USD 210.3 Million in 2018 and expected to reach USD 744.6 Million by 2025 with the CAGR of 19.8% over the forecast period.

Human Microbiome Market report is segmented on the basis of product type, diseases, application and region & country level. Based on product type, global human microbiome market is classified as probiotics, prebiotics, symbiotics, and others. Based upon diseases, global human microbiome market is classified into obesity, diabetes, autoimmune disorder, cancer, gastrointestinal disorders, central nervous system disorders, and others. Based upon application, global human microbiome market is classified as therapeutics and diagnostics.

Get Sample of This Report@ https://brandessenceresearch.com/requestSample/PostId/483

Market Analysis of Human Microbiome–

The human microbiome is the aggregate of all microbiota that resides on or within any of a number of human tissues and bio fluids, including the skin, mammary glands, placenta, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, biliary, and gastrointestinal tracts. It includes; bacteria, archaea, fungi, protists and viruses. As per recent estimates, a human body harbors microorganism having a ratio of 3:1 compared to the number of human cells present. The relationship of most microbes with the human bodies ranges from being commensal and mutualistic to neutral and harmful. Human microbiome-based therapies are available in the form of foods, prebiotics, diagnostic devices, probiotics, medical foods, drugs, and supplements. Technological advancements in metagenomics and next-generation sequencing have made microbiome-based testing easier and cheaper, and have led to the rapid analysis of the genomic content of microorganisms from human sample. This has boosted the development process for microbiome-based diagnostics.

Key Players-

Global human microbiome market report covers prominent players like Avidbiotics Inc., Avidbiotics Corp., 4D Pharma, Series Therapeutics, Second Genome, Enterome, MicroBiome Therapeutics, LLC, Rebiotix Inc., Yakult Honsha Co., Ltd., Osel Inc., Vedanta Biosciences, Inc., Metabiomics Corporate, Synthetic Biologics, Inc., DuPont, BiomX Ltd., and others.

The regions covered in this human microbiome market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Human Microbiome is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Market Segmentation: –

By Product Type:

Probiotics, Prebiotics, Symbiotics, Other Products

By Application:

Therapeutics, Diagnostics

Market Dynamics–

The increasing incidences of lifestyle diseases are expected to drive the growth of the global human microbiome market. According to the World Health Organization, in 2016, 13% of world population (adults) was obese. As per New Era of Treatment of Obesity and Metabolic Disorders, published in 2016, microbes residing in the human gastrointestinal tract act as an endocrine organ, whose composition and functionality contribute to the development of obesity. However, stringent government regulations related to the approval of human microbiome-based therapies are creating a major weakness to the growth of the market. Moreover, growing investments by governments in the development of human microbiome-based therapies are creating abundant growth opportunities for the global market for human microbiome.

North America is Expected to Dominate the Global Market–

North America is expected to dominate the global human microbiome market and held major market share due to the growing funding and research and development activities by companies and research institutes in this region. The presence of a large number of players who are adopting various initiatives such as investment in research and development for the development of the new therapeutic area for microbiome to prevent health issues such as irritable bowel syndrome, immune diseases, etc. is further contributing to the market in this region.

Full Research Report @ https://brandessenceresearch.com/healthcare/human-microbiome-market-development

About us: Brandessence Market Research and Consulting Pvt. Ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Website: https://brandessenceresearch.com/

Article: https://businessstatsnews.com

Blog: http://www.dailyindustrywatch.com

Blog: https://marketsize.biz

Blog: https://technologyindustrynews.com

Blog: https://marketstatsreport.com

Blog: https://tcbiznews.com/

#Human Microbiome Market #Human Microbiome Market Size #Human Microbiome Market Share #human microbiome market growth

0 notes

pharmanewstrands-blog · 5 years

Text

Insulin Market - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

The demand for insulin production is increasing to meet the treatment demand of the rising number of diabetic patients relying on insulin. This has led to increasing competition among market players to develop new insulin drugs in the market.

Insulin helps in promoting protein synthesis, glycogenesis, and glycolysis and in uptake of various ions. Earlier, insulin was isolated from sheep, and pigs, but later on, genetically modifying bacterial cells are also used to produce human insulin. Current treatment relies on developing commercial human insulin by recombinant DNA technology.

New product development and launches are expected to drive growth of global insulin market

Oramed Pharmaceuticals, in May 2018, developed the first oral drug delivery system, which stimulates the natural process of insulin in the liver. This insulin product is in phase II of clinical trial under the U.S. Food and Drug Administration (FDA) and this will provide efficient and safer method for delivering insulin therapy to patients.

Furthermore, in February 2018, Sanofi Aventis launched Toujea in India, a next generation basal insulin, with once or daily usage forms which improves glycemic control in adults with type 1 and type 2 diabetes. Increasing investment on research, development, and manufacturing of anti-diabetic drugs is expected to boost global insulin market

Increasing research activities for the development of innovative diabetic management drugs by using technology such as delivering insulin without needle provides better opportunities for manufacturers in the global insulin market. For instance, from year 1952 to 2017, the American Diabetes Association (ADA) has invested US$ 807.4 million for over 4,700 research projects on diabetes.

In September 2017, Biocon Limited received funding from Juvenile Diabetes Research Foundation (JDRF) to study safety and efficacy of insulin Tregopil in diabetic patients. Insulin Tregopil is currently undergoing a pivotal Phase II/III study in type 2 diabetes patients in India. This fast acting insulin can improve post prandial glucose control with fewer side effects.

Request A Sample Copy:

https://www.coherentmarketinsights.com/insight/request-sample/2183

Moreover, in September 2018, GeneSys Biologics Private Limited expanded research, development, and manufacturing unit in India for the development of insulin and its analogues biosimilars, allowing its research and development unit for commercial manufacturing.

Development of the insulin pens by various manufacturers is also expected to boost the global insulin market. For instance, in August 2018, Julphar Gulf Pharmaceutical Industries, one of the largest pharmaceutical company of the Middle East and Africa collaborated with Becton, Dickinson (BD) to sell disposable insulin pens in United Arab Emirates (UAE) region and are in final stage of approval and registration. Through this agreement, Julphar’s human insulin formulations Jusline R, Jusline N, and Jusline 30/70 will be available through BD’s portfolio of BD Vystra disposable pens.

However, increasing cost of insulin products especially drugs and stringent regulatory norms for approval of new drugs may hamper growth of the market. For instance, according to the Pharmaceutical Care Management Association (PCMA) report in May 2018, insulin price has increased by 10 folds in the past few years. According to PCMA, prices for Humulin/ Novolin have increased from US$ 25 per prescription in 1985 to around US$ 300 in 2016. Also, prices for long-acting insulins have increased from around US$ 100 per prescription in 2007 to around US$ 400 in 2016.Thus, increasing cost of such insulin therapies are restraining the global insulin market growth.

Global Insulin Market - Regional Analysis

On the basis of region, the global insulin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in terms of market share in the global insulin market, owing to increasing cases of diabetes, and geriatric population in this region. For instance, according to the Centers for Disease Control and Prevention report 2017, over 100 million adults are suffering with diabetes in the U.S in 2017. Asia Pacific region is expected to witness higher growth due to increasing awareness for diabetic care, favorable government policies, and increasing R&D investments by larger companies.

Global Insulin Market – Competitive Landscape

Key players operating in the global insulin market include Eli Lilly and Company, Novo Nordisk A/ S, Julphar Gulf Pharmaceutical Industries, Sanofi S.A., Biocon Limited, GlaxoSmithKline, and Wockhardt. These companies are adopting strategies such as mergers, acquisitions, expansions, collaborations, and new product launches to retain their position in the global insulin market. For instance, in August 2018, Novo Nordisk acquired Ziylo to develop smart, glucose responsive insulin (GRIs), ensuring optimal glucose control and reducing risk of hypoglycemia.

Global Insulin Market – Taxonomy

The global insulin market is analyzed based on the following segmentations:

By Product Type

Drugs,Rapid Acting,Humalog,Novolog,Apidra,Short Acting,Novolin R

Humulin R,Intermediate Acting,Humulin N,Novolin NLong Acting

Levemir,Degludec,antus,Basaglar,Premixed,Humalog

Mix,Novolog Mix,Drug Delivery Devices,Pens,Syringes

By Distribution Channels

Hospital Pharmacies,Retail Pharmacies,Online Pharmacies

By Region

North America,Latin America,Europe,Asia Pacific,Middle East,Africa

Click To Read More On Insulin Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:[email protected]

#insulin market insulin market trends insulin market growth

0 notes

smitadeshmukh123 · 7 years

Text

Pain Management Therapeutics Market: Rising Geriatric Population and Favorable Regulatory Scenario to Boost Consumption of Pain Management Drugs

With generic medicines accounting for a more than two-thirds of the global pain management therapeutics market, several small- and medium-scale generic drug manufacturers will venture in the market and make it highly saturated in the near future, states TMR in a recent report. The segment of branded pain management therapeutics features the presence of some of the leading international pharmaceutical giants, including Merck & Co, Inc. Pfizer,Inc., Endo Health Solutions, Johnson & Johnson, and Purdue Pharma LP.

In the branded drugs segment, the top two companies, Pfizer,Inc. and Purdue Pharma LP, accounted for over 50% share in 2015. Over the forecast period, the overall share of the branded drugs manufacturers in the global pain management therapeutics market will further decline. “Major vendors will lose market share to emerging vendors such as Depomed, Inc. and AstraZeneca plc. and the competition in the generic drugs segment will further intensify,” quotes a TMR analyst.

This 130 page report gives readers a comprehensive overview of the pain management therapeutics market. Browse through 13 data tables and 64 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/pain-management-therapeutics.html

Alarming Rise in Prevalence of Chronic Diseases Emerges as High-impact Driver

The number of patients suffering from chronic pain is rising at a substantial pace globally. According to the WHO, nearly 116 mn people were suffering from chronic pain in 2011 in the U.S. alone. According to another survey, one in five people in Europe suffer from chronic pain every year.

The rising prevalence of chronic diseases such as a variety of cancers and diabetes further contribute to the further contributes to the number of people suffering from chronic pain, encouraging the use of pain management drugs. Medications for alleviating the pain occurring from cancer therapy and from the intrusion of cancer cells in bones and other body parts, for instance, accounted for over 28% share of the overall pain management therapeutics market’s overall valuation in 2015.

Rising Geriatric Population and Favorable Regulatory Scenario to Boost Consumption of Pain Management Drugs

The vast rise in the world’s geriatric population is also expected to emerge as a key growth driver for the global pain management therapeutics market from 2106 to 2024. Aged people are more prone to diseases such as arthritis, joint or bone pain, epilepsy, depression, nerve damage, diabetic neuropathy, and a variety of injuries owing to low immunity levels or gene alteration. The global population of geriatrics (people aged more than 65 years) is expected to rise to 2 bn by 2050, accounting for nearly 22% of the projected global population by then. This demographic will lead to a substantial rise in the overall global demand for numerous pain management drugs, thereby driving the global pain management therapeutics market.

Additionally, favorable regulations are playing a key role in the increased rate of development, approval, and commercialization of novel molecule combinations and drug delivery techniques in the pain management therapeutics sector. The instigation of a large number of regulatory healthcare reforms, favoring development of methods for the improved diagnosis and treatment of chronic pain, will help the pain management therapeutics tread along a promising growth path in the next few years.

Patent Expiries of Blockbuster Drugs and Rising Uptake of Generics Could Pose Existential Threat to Established Players

Request a sample of this report to know what opportunities will emerge in the rapidly evolving pain management therapeutics market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1059

Impending patent expiries of several blockbuster pain management drugs in the global market is one of the key high-impact challenges for the global pain management therapeutics market presently. Cheaper generic versions of once high-earning drugs will deal a huge blow to the overall revenues of several established vendors in the global pain management therapeutics market in the next few years.

The factor will also cause a substantial decline in the overall revenues of the global market. Moreover, the rapid influx of several new vendors with generic versions of once groundbreaking medications will lead to intense competition in the market for generic drugs for pain management therapeutics.

In terms of product types, the global pain management therapeutics market is presently dominated by opioids and Non-steroidal Anti-inflammatory Drugs (NSAIDS), which collectively accounted for over 52% of the market’s overall revenues in 2015. North America dominated the market, accounting for over 56% of the overall market in the same year.

On a whole, the global pain management therapeutics market is expected to expand at a 3.7% CAGR over the period between 2016 and 2024. At this pace, the market is expected to rise from a valuation of US$60.2 bn in 2015 to US$83.0 bn by 2024.

This review of the global pain management market is based on a recent market research report, titled “Pain Management Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016-2023.”

#Pain Management Therapeutics Market

0 notes

healthy-insights · 8 years

Text

Pain Management Therapeutics Market: Latest Trends,Analysis & Insights 2024

For more info Get a copy of Sample Brochure :

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1059

Alarming Rise in Prevalence of Chronic Diseases Emerges as High-impact Driver

Rising Geriatric Population and Favorable Regulatory Scenario to Boost Consumption of Pain Management Drugs

Patent Expiries of Blockbuster Drugs and Rising Uptake of Generics Could Pose Existential Threat to Established Players

For this study, the market is segmented as follows:

Global Pain Management Therapeutics Market Revenue, by Therapeutics

Anticonvulsants

Antidepressants

Anesthetics

Non-steroidal Anti-inflammatory Drugs (NSAIDS)

Opioids

Antimigraine Agents

Other Non-narcotic Analgesic

Oxycodones

Hydrocodones

Tramadol

Others (Morphine, Codeine, Fentanyl, Meperidine, Methadone)

Global Pain Management Therapeutics Market Revenue, by Indication

Neuropathic Pain

Fibromyalgia

Chronic Back Pain

Arthritic Pain

Migraine

Post-operative Pain

Cancer Pain

Global Pain Management Therapeutics Market, by Geography

North America

Europe

Asia Pacific (APAC)

Rest of the World (RoW)

U.S.

Canada

Germany

U.K.

China

Japan

Brazil

Mexico

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com

0 notes

type2diabetestreatments-blog · 8 years

Text

13 Diabetes Products in the Pipeline

New Post has been published on http://type2diabetestreatment.net/diabetes-news/13-diabetes-products-in-the-pipeline/

13 Diabetes Products in the Pipeline

Welcome to the future of diabetes management

By Tracey Neithercott, Allison Tsai, and Kimberly Goad March 2017

Innovation is moving faster than ever, and that’s true in the diabetes world, too. Each year, new products are pushed out of the pipeline in the hopes of making diabetes management easier and more accurate. Here are some we eagerly await.

Stand-Alone CGM

There’s been talk about Medtronic’s latest combo continuous glucose monitor (CGM)–pump, but lost in all that chatter is that the company has set its sights on a device for people taking multiple daily injections, too. Enter the Guardian Connect, a stand-alone continuous glucose monitor (not connected to a pump). Every five minutes, the CGM will transmit a reading to a smart device (Apple first; Android later), where you can view data or send readings and reports to family, caregivers, or a health care provider. The device will connect with the Sugar IQ app, which uses IBM’s Watson supercomputer to mine the data and provide insight—say, your glucose trends low around 3 p.m. each day. Guardian Connect is currently under review by the Food and Drug Administration (FDA).

Artificial Pancreas

To reach its goal of a partial artificial pancreas—a system that will automatically deliver basal insulin and bolus correction doses—by the summer of 2018, Tandem Diabetes is teaming up with CGM manufacturer Dexcom for a three-part project. First comes the integration of Dexcom’s G5 sensor with Tandem’s T:slim X2 pump. FDA clearance is expected by midyear. After that: an X2 pump with CGM integration that tracks glucose trends, then stops insulin delivery before your glucose drops too low—estimated to release by the end of the year. But the big deal is a pump that does all of the above, plus uses CGM data to automatically deliver basal insulin and bolus correction doses when your glucose rises. You’d still need to enter carbs and bolus for meals. If all goes according to plan, that could be on the market by June 2018.

Smart Cap

Common Sensing’s Gocap can log doses from any disposable, prefilled insulin pen. Attach it to your pen and, using optical sensors, it will determine how much insulin you’ve delivered. Doses are displayed on the screen and automatically logged, making it easy for you to share with your provider and family. Other features include wireless communication with certain meters and an app that helps translate your dosing and blood glucose data so you can better manage your diabetes. Pilot clinical studies are underway, and the cap is expected to be available through certain insurance plans sometime this year.

Sensor Log

Another memory tool for insulin pens is in the early design stages. Insulog uses sensors to determine how much insulin you’ve taken—and when. The device snaps onto the side of an insulin pen and displays information on a digital screen. It also streams data via Bluetooth to a companion app.

Disposable CGM

Dexcom is teaming up with Verily (the life sciences division of Google’s parent company, Alphabet) to create a disposable continuous glucose monitoring system for people with type 2 diabetes. Over the course of its 14-day lifespan, a sensor would send your readings to a smartphone app so you can easily share with family or your health care provider. At launch, the above-skin portion of the sensor will be smaller than a quarter, but by 2020 the company hopes to have reduced it to the size of an M&M candy. An added bonus: The device won’t require finger-stick calibration. Dexcom sees the disposable CGM as a device people with type 2 could use as needed for greater insight into their glucose levels—say, with diet or exercise changes. The system is expected to release in 2018.

Insulin Pill

One of the elusive goals of insulin research is developing a pill you can take daily. There’s just one problem: Because insulin is a protein-based drug, the stomach digests it before it has time to do your blood glucose any good. Professor Mary McCourt, PhD, and her team at Niagara University are working on a solution. They theorize that by putting insulin into a container made of molecules the stomach won’t break down, they can create an insulin pill that’ll pass through the stomach. Their technology, named Cholestosome, uses naturally occurring lipid molecules—the building blocks of fats—to create cavities that can hold the insulin. Because of its makeup, Cholestosome can resist breakdown by stomach acid as it passes through the stomach. Once in the intestines, Cholestosome is absorbed, and insulin is released. The researchers are in the early stages of development, and more animal studies are ahead.

Implantable CGM

Not a fan of replacing your CGM sensor every week? In the future, you might go as long as three months between sensor changes. Senseonics’ system includes a 90-day, pill-sized sensor that’s inserted beneath the skin of the upper arm and a removable transmitter (a bit larger than traditional CGM transmitters) that rests just above, on top of the skin. Using fluorescent technology, the sensor monitors glucose, then wirelessly sends the data to the transmitter. That, in turn, sends data to a smartphone app. Sensor insertion and removal is done by a doctor during a short office visit. Within 24 hours, users can begin getting readings, and within 48 hours the insertion site will be fully healed. The CGM is currently available in Europe and was submitted to the FDA for premarket approval in late 2016. The goal: a U.S. launch by the end of this year or early 2018.

Tubeless Artificial Pancreas

Insulet is conducting clinical trials for its Omnipod Horizon partial artificial pancreas system that’ll run on its tubeless pump and with a CGM sensor—the company hopes to use Dexcom’s next-generation G6 version—and an Android-based handheld receiver to control functions. The system, which users will be able to customize using the handheld device, automatically controls basal insulin, though users will need to manually deliver mealtime boluses. Testing on the system has already begun, and in 2018 Insulet plans to conduct a pivotal trial, with a product release tentatively scheduled for 2019.

Patch Pump

In the pipeline for people with type 2: a lower-tech insulin delivery option from Becton, Dickinson, and Co. The disposable device delivers both basal and bolus insulin directly from a patch that’s worn on the skin for up to three days. A Bluetooth receiver wirelessly communicates with the device and relays information to a smartphone app. Look for it in 2018.

Retinopathy Mask

Long-term high blood glucose can deprive the retina of oxygen and cause growth of weak blood vessels that leak, all of which impairs vision. The current treatments for the condition, known as diabetic retinopathy: injectable drugs, laser therapy, and surgery. But in the future, you may be able to treat it while you sleep. PolyPhotonix’s Noctura 400 Sleep Mask emits low-level light through your eyelids during slumber, which the company claims reduces the amount of oxygen the eyes need during the night and minimizes the growth of weakened vessels. (More research is needed to determine whether this technology can effectively treat diabetic retinopathy.) Right now, it’s available only in the United Kingdom, but PolyPhotonix has submitted the product for FDA review.

Coming Soon

These products are just around the corner

Medtronic MiniMed 670G

This is what you’ve been waiting for: a partial artificial pancreas, a hybrid closed-loop insulin pump that automatically adjusts your basal insulin delivery based on your glucose level. (You still need to manually bolus for meals, though.) The system, which includes a more accurate CGM sensor, has received FDA approval and is set to launch this spring.

Xultophy

Both insulin degludec (Tresiba) and liraglutide (Victoza) have been out on the market for years. Now Novo Nordisk is combining the two in a mix that will treat type 2 diabetes in a new way. The FDA has approved the injectable drug, Xultophy, and it’s set to release by midyear.

OneTouch Vibe Plus

The FDA has cleared Animas’s latest insulin pump, which is integrated with Dexcom’s G5 Mobile CGM system. Download Dexcom’s app onto a smartphone to get glucose readings, trends, and to program the pump to deliver insulin. Friends, caregivers, and health care providers using another app can see your real-time glucose data. No word yet on the product’s specific launch date.

Type 2 Diabetes Treatment Type 2 Diabetes Diet Diabetes Destroyer Reviews Original Article

0 notes

market-research-future · 4 years

Text

Africa Medical Devices Market Key Companies Profile, Applications and Trends

Competitive Analysis

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1813

Africa Medical Devices Market Regional Analysis

Overview

Moreover, rising economic growth also drive the market in this region. According to the World Bank Group, in 2016, GDP of the Middle East & North Africa experienced the growth in GDP by 4.89%.

Browse Detailed Table of Content at: https://www.marketresearchfuture.com/reports/africa-medical-devices-market-2845

Brows More Healthcare Related Research Reports:

Infrared Spectroscopy Devices Market Size, Trends | Growth Analysis, 2023

Asia-Pacific Glaucoma Treatment Market Trends, Size Analysis | Applications, 2023

Diabetes Market Research Report Forecast To 2023 | MRFR

About Market Research Future:

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]

0 notes

technicallyyoungkitten · 4 years

Text

Wearable Patch Market -Size, Share, Outlook, and Opportunity Analysis, 2020- 2027

The global wearable patch market size is expected to be valued at US$ 318.1 million in 2019, and is expected to exhibit a CAGR of 22.9% over the forecast period (2019-2027).

Browse Summary of the Research Report-https://www.coherentmarketinsights.com/market-insight/wearable-patch-market-2891

Rising technological advancements in wearable patch is anticipated to drive the market growth over the forecast period

Key Players

Request A Sample Copy -https://www.coherentmarketinsights.com/insight/request-sample/2891

About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] ******************************************************************************************************************

0 notes

market-research-future · 4 years

Text

Africa Medical Devices Market Profile, Opportunities, Global Industry Analysis By 2023

Africa Medical Devices Market Regional Analysis

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1813

Overview

Moreover, rising economic growth also drive the market in this region. According to the World Bank Group, in 2016, GDP of the Middle East & North Africa experienced the growth in GDP by 4.89%.

Competitive Analysis

Companies are continuously engaged in merger and acquisition activities for the development of the best medicine to cure affected population. Although the government stick rule hindering the growth of the market. In May 2017, Baxter International Inc. and Mayo Clinic announced a collaboration for the research and development to advance a spectrum of therapeutic areas to minimize the unmet patient needs. These collaborations help market players to lead the market of Africa. Most of the players from this region involve in the collaboration with global players to get advanced technology, which help them to maximize the market share in this region. Although limited infrastructure, lack of physicians, and restricted funding and reimbursement policy are the restraints factor for the growth of the market.

Browse Detailed Table of Content at: https://www.marketresearchfuture.com/reports/africa-medical-devices-market-2845

Brows More Healthcare Related Research Reports:

Infrared Spectroscopy Devices Market Size, Trends | Growth Analysis, 2023

Asia-Pacific Glaucoma Treatment Market Trends, Size Analysis | Applications, 2023

Diabetes Market Research Report Forecast To 2023 | MRFR

About Market Research Future:

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]

0 notes

market-research-future · 4 years

Text

Africa Medical Devices Market Key Companies Profile, Size, Share By 2023

Africa Medical Devices Market Regional Analysis

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1813

Overview

Moreover, rising economic growth also drive the market in this region. According to the World Bank Group, in 2016, GDP of the Middle East & North Africa experienced the growth in GDP by 4.89%.

Competitive Analysis

Companies are continuously engaged in merger and acquisition activities for the development of the best medicine to cure affected population. Although the government stick rule hindering the growth of the market. In May 2017, Baxter International Inc. and Mayo Clinic announced a collaboration for the research and development to advance a spectrum of therapeutic areas to minimize the unmet patient needs. These collaborations help market players to lead the market of Africa. Most of the players from this region involve in the collaboration with global players to get advanced technology, which help them to maximize the market share in this region. Although limited infrastructure, lack of physicians, and restricted funding and reimbursement policy are the restraints factor for the growth of the market.

Browse Detailed Table of Content at: https://www.marketresearchfuture.com/reports/africa-medical-devices-market-2845

Brows More Healthcare Related Research Reports:

Infrared Spectroscopy Devices Market Size, Trends | Growth Analysis, 2023

Asia-Pacific Glaucoma Treatment Market Trends, Size Analysis | Applications, 2023

Diabetes Market Research Report Forecast To 2023 | MRFR

About Market Research Future:

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]

0 notes

market-research-future · 4 years

Text

Africa Medical Devices Market Segmentation, SWOT Analysis and Dynamics To 2023

Overview

Moreover, rising economic growth also drive the market in this region. According to the World Bank Group, in 2016, GDP of the Middle East & North Africa experienced the growth in GDP by 4.89%.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1813

Africa Medical Devices Market Regional Analysis

The Africa medical devices market is growing rapidly in Africa region owing to upgrade of hospitals, introduction of health insurance policy, and rapidly growing middle-income group. Government is focussing more to improve the life of their citizen, thus they are more focusing on the establishment of best hospitals in the region. This region is more focusing towards new technology and advance treatment option; thus the local players are focusing more into mergers and acquisition and research and development programs for the development of Medical devices. These are the factors which are fuelling the growth of the market of medical devices with the significant rates in this region.

Competitive Analysis

Companies are continuously engaged in merger and acquisition activities for the development of the best medicine to cure affected population. Although the government stick rule hindering the growth of the market. In May 2017, Baxter International Inc. and Mayo Clinic announced a collaboration for the research and development to advance a spectrum of therapeutic areas to minimize the unmet patient needs. These collaborations help market players to lead the market of Africa. Most of the players from this region involve in the collaboration with global players to get advanced technology, which help them to maximize the market share in this region. Although limited infrastructure, lack of physicians, and restricted funding and reimbursement policy are the restraints factor for the growth of the market.

Browse Detailed Table of Content at: https://www.marketresearchfuture.com/reports/africa-medical-devices-market-2845

Brows More Healthcare Related Research Reports:

Blood Glucose Test Strip Packaging Market– Forecast to 2021 | MRFR

Clinical Intelligence Market Research Report- Forecast to 2023 | MRFR

Labyrinthitis Market Size, Growth Analysis | Industry Trends, 2023

About Market Research Future:

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]

0 notes

market-research-future · 5 years

Text

Africa Medical Devices Market Analysis By Growth, Trend, Scope | Forecast to 2023

Africa Medical Devices Market Size and Share Analysis by Product type (Monitoring Devices, Diagnostic devices, Diagnostic Molecular Devices, Drug delivery devices, Surgical Devices, Bio implants and Stimulation Devices, Automation and Robotics and Others), by Therapeutic Application (General Surgery, Diagnostic Imaging, Respiratory, Orthopedics, Cardiovascular, Dental, Neurology, Ophthalmology, Ear-Nose-Throat (ENT), Nephrology and Urology, and Others) and by End User - Forecast to 2023

The Africa Medical Devices Market is growing with a steady pace; mainly due to the rapidly growing middle-income group, increasing healthcare expenditure, increasing number of medical tourists, proliferation of hospitals, government programs and support, and increasing incidence of lifestyle diseases. Moreover, rising economic growth also drive the market in this region. According to the World Bank Group, in 2016, GDP of the Middle East & North Africa experienced the growth in GDP by 4.89%. It is expected that Africa’s macroeconomic climate over the next decade will expand the health care gap, as higher incomes will create new demand for the medical devices market. Additionally, government also introduces some laws for maintaining the quality of medical devices. According to a report published by the International Diabetes Federation, in 2017, more than 16 million people are suffering with diabetes in the AFR Region. Increasing number of incidences are the main factors which drag the attention of players towards this region.

Companies are continuously engaged in merger and acquisition activities for the development of the best medicine to cure affected population. Although the government stick rule hindering the growth of the market. In May 2017, Baxter International Inc. and Mayo Clinic announced a collaboration for the research and development to advance a spectrum of therapeutic areas to minimize the unmet patient needs. These collaborations help market players to lead the market of Africa. Most of the players from this region involve in the collaboration with global players to get advanced technology, which help them to maximize the market share in this region. Although limited infrastructure, lack of physicians, and restricted funding and reimbursement policy are the restraints factor for the growth of the market.

Africa Medical Devices Market Regional Analysis

The medical devices market is growing rapidly in Africa region owing to upgrade of hospitals, introduction of health insurance policy, and rapidly growing middle-income group. Government is focussing more to improve the life of their citizen, thus they are more focusing on the establishment of best hospitals in the region. This region is more focusing towards new technology and advance treatment option, thus the local players are focusing more into mergers and acquisition and research and development programs for the development of Medical devices. These are the factors which are fuelling the growth of the market of medical devices with the significant rates in this region.

Most of the major players such as Johnson & Johnson (U.S.), Mindray Medical International Limited (China), Koninklijke Philips Electronics NV (Netherlands), Siemens AG (Germany), Toshiba Medical Systems Corporation (Japan), GE Healthcare (U.K), Medtronic Public Limited (U.S.), Baxter International Inc. (U.S.), Cardinal Health, Inc. (U.S.), Saudi Pharmaceutical Industries & Medical Appliances Corporation (Africa), and Al Faisaliah Medical Systems (Africa) are looking forward in this region to minimize the gap of between demand and supply of advance medical devices and maximize the profit sharing ration. Company such as Koninklijke Philips Electronics NV, Siemens AG, Medtronic Public Limited, and GE Healthcare have already a huge presence in Africa region owing to the collaboration they made and strategy of expanding their sales network within the region. The markets of Africa region are very different and still shaping and growing. Although most of the products are imported within the region, but the government is focusing to develop these equipment in their premises to minimize the cost of medical devices.

Brows More Healthcare Related Research Reports:

Ureteral Obstruction Market Trends, Application | Share Analysis, 2023

Lichen Sclerosus Treatment Market Trends, Size Analysis | Applications, 2023

Antihistamine Drugs Market Size, Application | Growth Analysis, 2023

About Market Research Future:

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]

0 notes